文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Review of the Role of HER2/neu in Colorectal Carcinomas.

作者信息

Achalla Lakshmi Sai Vijay, Shinde Raju K, Jogdand Sangita, Vodithala Sahitya

机构信息

Department of Surgery, Acharya Vinoba Bhave Rural Hospital (AVBRH) Jawaharlal Nehru Medical College (JNMC) Datta Meghe Institute of Medical Sciences (DMIMS), Wardha, IND.

Department of General Surgery, Datta Meghe Institute of Medical Sciences (DMIMS) University, Wardha, IND.

出版信息

Cureus. 2022 May 27;14(5):e25409. doi: 10.7759/cureus.25409. eCollection 2022 May.

DOI:10.7759/cureus.25409
PMID:35774672
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9236668/
Abstract

Human epidermal growth factor receptor 2 (HER2/neu) is an oncogenic driver and a proven target for treatment of breast and gastric cancers. The role of HER2/neu and its blockage in various tumors, particularly colorectal adenocarcinoma has been widely explored following the revolutionary impact of anti-HER2/neu therapy in breast and gastric carcinoma patients. This review aimed to highlight the most recent updates on the significance of HER2/neu as a prognostic and predictive factor in these tumors together with its subsequent possible therapeutic indications from preclinical tests and ongoing assessments testing anti-HER2/neu agents in colorectal carcinoma (CRC). In the near future with a growingly tailored therapeutic approach toward cancers, HER2/neu targeted therapeutic strategies may blend into CRC treatment methods.

摘要

相似文献

[1]
Review of the Role of HER2/neu in Colorectal Carcinomas.

Cureus. 2022-5-27

[2]
Human epidermal growth factor receptor 2 (Her2) testing for uterine serous carcinoma: Report of scenarios of unusual overexpression.

Gynecol Oncol Rep. 2020-3-16

[3]
Laboratory testing for HER2/neu in breast carcinoma: an evolving strategy to predict response to targeted therapy.

Cancer Control. 2001

[4]
The Prognostic Significance of the Overexpression of HER-2/ neu in Korean Gastric Carcinomas and the In Vitro Effects of Anti-HER-2/neu Antibody on Cell Growth in the Gastric Carcinoma Cell Lines.

Cancer Res Treat. 2003-4

[5]
Human epidermal growth factor receptor 2 neu expression in head and neck squamous cell cancers and its clinicopathological correlation: Results from an Indian cancer center.

Indian J Pathol Microbiol. 2018

[6]
Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.

Ann Oncol. 2005-8

[7]
HER2 Oncogene Amplification and Immunohistochemical Profiling in Gastric Adenocarcinoma.

Discoveries (Craiova). 2018-12-31

[8]
Targeting HER2: recent developments and future directions for breast cancer patients.

Semin Oncol. 2001-12

[9]
HER2/neu testing in primary colorectal carcinoma.

Br J Cancer. 2014-11-11

[10]
Narrative review on the evolving role of HER2/neu targeting in uterine serous cancers.

Ann Transl Med. 2024-8-1

引用本文的文献

[1]
Prognostic and Predictive Significance of Primary Tumor Localization and HER2 Expression in the Treatment of Patients with KRAS Wild-Type Metastatic Colorectal Cancer: Single-Centre Experience from Serbia.

J Pers Med. 2024-8-20

[2]
HER2-neu Expression and Survival in Colorectal Cancer in the South of Egypt; Immunohistochemistry and Genetic Study.

Asian Pac J Cancer Prev. 2024-6-1

本文引用的文献

[1]
HER2-specific chimeric antigen receptor-T cells for targeted therapy of metastatic colorectal cancer.

Cell Death Dis. 2021-11-27

[2]
Global colorectal cancer burden in 2020 and projections to 2040.

Transl Oncol. 2021-10

[3]
Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer.

Int J Mol Sci. 2021-6-24

[4]
Precision Oncology Strategy in Trastuzumab-Resistant Human Epidermal Growth Factor Receptor 2-Positive Colon Cancer: Case Report of Durable Response to Ado-Trastuzumab Emtansine.

JCO Precis Oncol. 2017-6-27

[5]
Prognostic and Predictive Value of HER2 Amplification in Patients With Metastatic Colorectal Cancer.

Clin Colorectal Cancer. 2018-5-19

[6]
Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer.

Ann Oncol. 2018-5-1

[7]
Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case.

ESMO Open. 2018-1-10

[8]
Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus.

Clin Cancer Res. 2018-1-23

[9]
Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer.

J Natl Compr Canc Netw. 2017-1

[10]
Frequency of Her2/neu expression in colorectal adenocarcinoma: a study from developing South Asian Country.

BMC Cancer. 2016-11-7

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索